Related Experiment Video
Updated: Aug 30, 2026

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
Published on: January 22, 2018
[Triamcinolone acetonide in the prevention of experimental proliferative vitreoretinopathy]
1Department of Ophthalmology, Xijing Hospital 4th Military Medical University, Xi-an.
Abstract:
Macrophages were used to induce an experimental model of proliferative vitreoretinopathy (PVR) for the evaluation of drug efficacy of triamcinolone acetonide in the prevention of PVR. After injection of macrophages into the rabbit vitreous, 1 mg of triamcinolone and 0.1 ml saline, respectively, were also injected into the vitreous of the treated group and the control group. Afterwards, on the 28th day, retinal detachment developed in 77% of the eyes in the control group and in 13% of the eyes in the treated group (n = 30, P < 0.01). The time of triamcinolone being cleared up from the vitreous was 35-63 days (average 45.5 days). Electroretinogram and transmission electron microscopic examinations demonstrated that up to 4 mg of triamcinolone was nontoxic to the retina. The results suggest that during inflammatory stage, the use of triamcinolone effectively and safely prevent the development of PVR.
Insights
Triamcinolone acetonide effectively prevents proliferative vitreoretinopathy (PVR) in rabbits by reducing retinal detachment. This drug was found to be safe for the retina at therapeutic doses.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy

